Being sceptical about meta-analyses: A Bayesian perspective on magnesium trials in myocardial infarction

International Journal of Epidemiology

Volumn 31, Issue 1, 2002, Pages 96-104

  Higgins, Julian P T ^a,b   Spiegelhalter, David J ^a  

^a MRC BIOSTATISTICS UNIT   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Bayes theorem; Magnesium sulphate; Meta analysis; Myocardial infarction

Indexed keywords

FIBRINOLYTIC AGENT; MAGNESIUM;

BAYESIAN ANALYSIS; MAGNESIUM; META-ANALYSIS;

ARTICLE; BAYES THEOREM; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART INFARCTION SIZE; HUMAN; HYPOTHESIS; META ANALYSIS; MORTALITY; POPULATION SIZE; PRIORITY JOURNAL; PUBLICATION; REPERFUSION INJURY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

EID: 0036205370     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/31.1.96     Document Type: Article

References (56)

1. Comments on 'Investigating therapies of potentially great benefit: ECMO' by JH Ware
2. Implications for trials in progress of publication of positive results
3. Bayesian approaches to randomised trials
4. Bayesian data monitoring in clinical trials
5. Meta-analysis in the design and monitoring of clinical trials
6. Bayesian interim analysis of phase II cancer clinical trials
7. Assessing whether to perform a confirmatory randomised clinical trial
8. Bayesian methods in health technology assessment: A review
9. Intravenous magnesium in acute myocardial infarction
10. Effects of intravenous magnesium in suspected acute myocardial infarction: Overview of randomised trials
11. The rationale of magnesium supplementation in acute myocardial infarction: A review of the literature
12. Magnesium therapy in acute myocardial infarction-double blind study
13. Magnesium therapy in acute myocardial infarction
14. Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)
15. Intravenous magnesium in acute myocardial infarction: An effective, safe, simple and inexpensive treatment
16. ISIS-4-a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium-sulphate in 58 050 patients with suspected acute myocardial infarction
17. Magnesium in acute myocardial-infarction
18. Meta-analysis of randomised trials: Looking back and looking ahead
19. Large-scale randomised evidence-large, simple trials and overviews of trials
20. Role of magnesium in reducing mortality in acute myocardial infarction: A review of the evidence
21. Misleading meta-analysis
22. Magnesium and myocardial-infarction
23. Bias in meta-analysis detected by a simple, graphical test
24. Cumulating evidence from randomised trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis
25. Overcoming the limitations of current meta-analysis of randomised controlled trials
26. Magnesium, myocardial infarction, meta-analysis and megatrials
27. Magnesium in acute MI: Timing is critical
28. Randomized trials of magnesium in acute myocardial infarction: Big numbers do not tell the whole story
29. Magnesium in acute myocardial infarction1 still an open question
30. Mega-trials and management of acute myocardial-infarction
31. Is there a place for magnesium in the treatment of acute myocardial infarction?
32. Review of clinical evidence-is there a role for supplemental magnesium in acute myocardial infarction in high-risk populations (patients ineligible for thrombolysis and the elderly)?
33. Magnesium in acute myocardial infarction: Overview of available evidence
34. Discordance between meta-analyses and large-scale randomized, controlled trials: Examples from the management of acute myocardial infarction
35. Magnesium and myocardial infarction
36. Results of randomized clinical trials of magnesium-can a consensus be reached?
37. Magnesium in acute myocardial infarction: Scientific, statistical, and economic rationale for its use
38. Meta-analysis in STATA
39. Beta blockade during and after myocardial infarction: An overview of the randomized trials
40. Meta-analysis in clinical trials
41. On estimating the relation between blood group and disease
42. Rationale and design of the magnesium in coronaries (MAGIC) study: A clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction
43. Intravenous magnesium for acute myocardial infarction (Protocol for a Cochrane review)
44. Bias in the one-step method for pooling study results
45. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature
46. A comparison of methods to detect publication bias in meta-analysis
47. A bivariate approach to meta-analysis
48. The population risk as an explanatory variable in research synthesis of clinical trials
49. Investigating underlying risk as a source of heterogeneity in meta-analysis
50. Analysing the relationship between treatment effect and underlying risk in meta-analysis: Comparison and development of approaches
51. Why sources of heterogeneity in meta-analysis should be investigated
52. Borrowing strength from external trials in a meta-analysis
53. Bayesian approaches to random-effects meta-analysis: A comparative study